Changchun Xinan (CCXA) is a privately owned business primarily serving the rural healthcare market with more than 100 plant-based pharmaceutical products in its portfolio.
American Oriental Bioengineering (AOBO) believes CCXA’s leading products will be highly complimentary to its existing product line and will also expand the variety of AOBO’s current product offering.
CCXA’s products cover both the prescription and OTC markets. In 2006, CCXA says it generated approximately $9 million (RMB68 million) in revenue annually with approximately 40 products contributing to the overall revenue.
Some of these products include Nubao, a blood circulation enhancer for treatment of premenstrual syndromes; Kanguzensheng Tablet for the treatment of bone spurs; Yakangling, a plant-based pharmaceutical product that treats gingivitis; and Nanbao, a plant based male sexual drive enhancer.
Tony Liu, CEO of AOBO stated: “We intend to identify ways to improve CCXA’s operating efficiency, add greater structure to the product line and implement a more beneficial pricing strategy. We look forward to enhancing overall productivity and efficiency in this business.”